We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ICIs combined with chemotherapy with or without antiangiogenic therapy (C/A) versus C/A alone in the ...
Patient perspectives of prior authorization: Understanding associations with care delivery and delays. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does ...
Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
The researchers find that in two different cancer types, combining Janus kinase (JAK) inhibitors with checkpoint inhibitor immunotherapy results in better clinical responses in patients with ...
ICIs, representing a revolutionary breakthrough in cancer immunotherapy, restore T-cell antitumor activity by targeting and blocking inhibitory immune molecules, thereby significantly extending the ...
Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...
Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...
Please provide your email address to receive an email when new articles are posted on . Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced ...
Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results